pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Cancer Program · news · pharmadog
← back to Cancer Program
News mentioning Cancer Program
69
stories
29d
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 16, 26
Merck wins first approval of a PCSK9 cholesterol pill
biopharma dive
Jul 15, 26
Merck ADC, in China study, shows potential to replace chemo in lung cancer
biopharma dive
Jul 15, 26
STAT+: Celcuity’s breast cancer drug approved, its first
stat
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jul 14, 26
STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year
stat
Jul 13, 26
Agenus surges on study pivot; Apnimed lines up an IPO
biopharma dive
Jul 2, 26
Roche KRAS drug succeeds in head-to-head lung cancer study
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 15, 26
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
biopharma dive
Jun 12, 26
Merck brings Welireg-Keytruda combo to treat kidney cancer
endpoints
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
Jun 2, 26
What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
endpoints
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
May 12, 26
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
onclive
May 11, 26
Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone
endpoints
May 11, 26
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
biopharma dive
May 11, 26
Biotech layoffs are easing, but is the worst over?
biopharma dive
May 8, 26
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
onclive
May 8, 26
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
onclive
May 8, 26
Lilly, Gilead lead pharma’s M&A boom
biopharma dive
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
May 7, 26
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
onclive
May 7, 26
Entrada shares dive as Duchenne results disappoint
biopharma dive
← prev
page 2 of 3
next →
